Cargando…

A Co-Delivery System of Curcumin and p53 for Enhancing the Sensitivity of Drug-Resistant Ovarian Cancer Cells to Cisplatin

In order to enhance the sensitivity of drug-resistant ovarian cancer cells to cisplatin (DDP), a co-delivery system was designed for simultaneous delivery of curcumin (CUR) and p53 DNA. Firstly, the bifunctional peptide K14 composed of tumor targeting peptide (tLyP-1) and nuclear localization signal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xinli, Fang, Zhou, Zhang, Min, Yang, Deyu, Wang, Shuyue, Liu, Kehai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321199/ https://www.ncbi.nlm.nih.gov/pubmed/32512936 http://dx.doi.org/10.3390/molecules25112621

Ejemplares similares

Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles
por: Khan, Muhammad Muzamil, et al.
Publicado: (2020)

Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
por: Bortot, Barbara, et al.
Publicado: (2020)

IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis
por: Wang, Houmei, et al.
Publicado: (2022)

Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment
por: Hu, Yuzhu, et al.
Publicado: (2020)

Sensitization of Resistance Ovarian Cancer Cells to Cisplatin by Biogenic Synthesized Silver Nanoparticles through p53 Activation
por: Ramezani, Tayebe, et al.
Publicado: (2019)

Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer
por: Zhang, Yumin, et al.
Publicado: (2016)

Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo
por: Ren, Xin, et al.
Publicado: (2016)

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tum3or cells
por: Bhatt, Michelle, et al.
Publicado: (2016)

p62 Promotes the Mitochondrial Localization of p53 through Its UBA Domain and Participates in Regulating the Sensitivity of Ovarian Cancer Cells to Cisplatin
por: Kong, Qinghuan, et al.
Publicado: (2022)

Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer
por: Xia, Xi, et al.
Publicado: (2011)

PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation
por: Kobayashi, Noriko, et al.
Publicado: (2013)

Overexpression of CCDC69 activates p14(ARF)/MDM2/p53 pathway and confers cisplatin sensitivity
por: Cui, Long, et al.
Publicado: (2019)

Nanoscale Metal–Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells
por: He, Chunbai, et al.
Publicado: (2014)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Vasohibin 2 Decreases the Cisplatin Sensitivity of Hepatocarcinoma Cell Line by Downregulating p53
por: Li, Zhanjun, et al.
Publicado: (2014)

Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer
por: Guo, Jianfeng, et al.
Publicado: (2021)

Construction of pH-sensitive targeted micelle system co-delivery with curcumin and dasatinib and evaluation of anti-liver cancer
por: Zeng, Xiangle, et al.
Publicado: (2022)

Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth
por: Yallapu, Murali M, et al.
Publicado: (2010)

ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA
por: Hou, Xin-Fang, et al.
Publicado: (2017)

miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8
por: Cui, Yajie, et al.
Publicado: (2018)

MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B
por: Niu, Qin, et al.
Publicado: (2019)

Efficacy of Polymer-Based Nanocarriers for Co-Delivery of Curcumin and Selected Anticancer Drugs
por: Alven, Sibusiso, et al.
Publicado: (2020)

Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells
por: Niimi, Kaoru, et al.
Publicado: (2014)

Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells
por: Leng, Yun, et al.
Publicado: (2021)

Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy
por: Xie, Jiajiang, et al.
Publicado: (2018)

Development of Novel pH-Sensitive Eudragit Coated Beads Containing Curcumin-Mesalamine Combination for Colon-Specific Drug Delivery
por: Heikal, Eman J., et al.
Publicado: (2023)

Downregulation of miR-3934-5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP1
por: Ren, Aijun, et al.
Publicado: (2019)

Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression
por: Zou, Jiao, et al.
Publicado: (2018)

The Effect of Resveratrol or Curcumin on Head and Neck Cancer Cells Sensitivity to the Cytotoxic Effects of Cisplatin
por: Bostan, Marinela, et al.
Publicado: (2020)

Enhanced anti-breast cancer efficacy of co-delivery liposomes of docetaxel and curcumin
por: Ye, Xi, et al.
Publicado: (2022)

Role of p53 in Cisplatin-Induced Myotube Atrophy
por: Matsumoto, Chinami, et al.
Publicado: (2023)

Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin
por: Shi, Yandong, et al.
Publicado: (2012)

Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway
por: Shang, Lei, et al.
Publicado: (2019)

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles
por: Xiong, Xunhao, et al.
Publicado: (2014)

Proteasome inhibitor MG132 enhances the sensitivity of human OSCC cells to cisplatin via a ROS/DNA damage/p53 axis
por: Zheng, Zheng, et al.
Publicado: (2023)

Nanoformulation of Polyphenol Curcumin Enhances Cisplatin-Induced Apoptosis in Drug-Resistant MDA-MB-231 Breast Cancer Cells
por: Karami, Parastoo, et al.
Publicado: (2022)

Blockade of TRIM59 enhances esophageal cancer cell chemosensitivity to cisplatin by upregulating p53
por: Liu, Rongfeng, et al.
Publicado: (2021)

Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy
por: Giusto, Elena, et al.
Publicado: (2022)

NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin
por: Lin, Chao, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3rha8lpbnt1db3k21k2lebj69k